Mineralys Therapeutics to Present Lorundrostat Data at ASN Kidney Week

Mineralys Therapeutics will present new data on its lorundrostat drug at the American Society of Nephrology (ASN) Kidney Week 2026. The company is developing medicines for hypertension and aldosterone-related adverse outcomes in conditions like chronic kidney disease and obstructive sleep apnea.